PREVENCION DEL CANCER DE MAMA





PREVENCION DEL CANCER DE MAMA

(especial para SIIC © Derechos reservados)
Evaluación de las opciones actualmente disponibles para la prevención del cáncer de mama y las que aún se encuentran en investigación.
Autor:
Victor Vogel
Columnista Experto de SIIC

Institución:
University of Pittsburgh Cancer Institute


Artículos publicados por Victor Vogel
Recepción del artículo
5 de Octubre, 2005
Aprobación
13 de Octubre, 2005
Primera edición
23 de Marzo, 2006
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
Los resultados combinados de los cuatro estudios sobre la prevención con tamoxifeno demostraron una disminución del 38% en la incidencia de cáncer de mama. El estudio más amplio acerca de la disminución del riesgo, el Breast Cancer Prevention Trial, realizado por el National Surgical Adjuvant Breast and Bowel Project, reveló que el tamoxifeno disminuía el riesgo de cáncer de mama invasor en un 49%. El tamoxifeno actualmente está aprobado para disminuir el riesgo de cáncer de mama. Sin embargo, debido a los efectos colaterales asociados, otros agentes están siendo investigados. El ensayo Study of Tamoxifen and Raloxifen fue diseñado para comparar su eficacia para disminuir el riesgo de cáncer de mama. Los inhibidores de la aromatasa también están siendo evaluados en el marco de la prevención. Otros agentes están siendo investigados para la quimioprevención. Se requieren especialmente nuevos agentes para el cáncer de mama con receptores de estrógeno negativos. El lavado ductal es un método no invasivo que se utiliza para una valoración del riesgo individualizada. Su utilidad futura puede ser tanto para auxiliar de la pesquisa como para evaluar los marcadores bioquímicos intermedios para agentes quimiopreventivos.

Palabras clave
Quimioprevención, tamoxifeno, inhibidores de la aromatasa, raloxifeno, lavado ductal


Artículo completo

(castellano)
Extensión:  +/-6.26 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
The combined results from the four tamoxifen prevention trials showed a 38% reduction in breast cancer incidence. The largest risk-reduction trial, the Breast Cancer Prevention Trail conducted by the National Surgical Adjuvant Breast and Bowel Project, revealed that tamoxifen reduced the risk of invasive breast cancer by 49%. Tamoxifen is currently approved for breast cancer risk reduction. However, because of side effects associated with tamoxifen, other agents are being investigated. The Study of Tamoxifen and Raloxifene is designed to compare the efficacy of tamoxifen and raloxifene in reducing breast cancer risk. Aromatase inhibitors are also being evaluated in the prevention setting. Other agents are being investigated for chemoprevention. Novel agents are especially required for estrogen receptor- negative breast cancer. Ductal lavage is a non-invasive method utilized for individualized risk assessment. Future utility of ductal lavage may be as an adjunct to screening as well a way to evaluate intermediate biochemical markers for chemopreventive agents.

Key words
Chemoprevention, tamoxifen, aromatase inhibitors, raloxifene, ductal lavage


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Obstetricia y Ginecología
Relacionadas: Atención Primaria, Farmacología, Medicina Farmacéutica, Oncología, Salud Pública



Comprar este artículo
Extensión: 6.26 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
  2. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101.
  3. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93-97.
  4. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-823.
  5. Cuzick J, Powles T, Veronesi U, et al: Overview of the main outcomes in breast cancer prevention trials. Lancet 361:296-300.
  6. Meinikow J, Paterniti D, Azari R, et al: Preferences of women evaluating risk of tamoxifen (Power) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103:1996-2005.
  7. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281:2189-2197.
  8. Cauley JA, Norton L, Lippman ME, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65:125-134.
  9. Martino S, Cauley JA, Barrett-Connor E, et al: Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22, 14S (July 15 Supplement), 2004.
  10. Vogel VG, Costantino JP, Wickerham DL, et al: The study of tamoxifen and raloxifene: Preliminary enrollment data from the randomized breast cancer reduction trial. Clin Breast Cancer 3:153-159.
  11. O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letters 330:156-160.
  12. Liu, X H, Rose, DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56:5125-5127.
  13. Hwang, D, Scollard D, Byrne J et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455-460.
  14. Parrett ML, Harris RL, Joarder FS et al. Cyclooxygense-2 gene expression in human breast cancer. Int J Oncol 10:503-508.
  15. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
  16. Schrey MP, Patel KV. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72:1412-1419.
  17. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97:2978-2987.
  18. Robertson FM, Parrett ML, Jorder FS, et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinoma. Cancer Lett 122:165-175.
  19. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br.J Cancer 84:1188-1192.
  20. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 63:6096-6101.
  21. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810.
  22. Baum M, Buzdar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139.
  23. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
  24. Cuzick J: Aromatase Inhibitors for breast cancer prevention. J of Clin Oncol 23:1636-1643.
  25. O’Shaughnessy JA, Ljung BM, Dooley WC, et al: Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 94:292-298.
  26. Dooley WC. Ductal lavage, nipple aspiration, and ductoscopy for breast cancer diagnosis. Breast Cancer 5:63-65.
  27. Arun B, Valero V, Cook E et al. Phase II chemoprevention trial of celecoxib using ductal lavage. Breast Cancer Res Treat 71:126a.
  28. Arun B. Ductal lavage and risk assessment of breast cancer. The Oncologist 9:599-605.
  29. Fabian CJ. Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J of Clin Oncol 23:1636-1643.
  30. Gasco M, Argusti A, Bonanni B, et al: SERMs in chemoprevention of breast cancer. European J Cancer 41:1980-9.
  31. Hampton T. Clinical trials point to complexities of chemoprevention for cancer. JAMA 294:29-31.

Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618